BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8383488)

  • 1. Identification of the Epstein-Barr virus nuclear antigen 2 transactivation domain.
    Horvath GC; Schubach WH
    Biochem Biophys Res Commun; 1993 Feb; 191(1):196-200. PubMed ID: 8383488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus nuclear antigen 2-estrogen receptor fusion proteins transactivate viral and cellular genes and interact with RBP-J kappa in a conditional fashion.
    Kempkes B; Pawlita M; Zimber-Strobl U; Eissner G; Laux G; Bornkamm GW
    Virology; 1995 Dec; 214(2):675-9. PubMed ID: 8553575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of transactivation, repression, and protein-protein interaction domains using GAL4-fusion proteins.
    Hsieh JJ; Hayward SD
    Methods Mol Biol; 2001; 174():259-69. PubMed ID: 11357653
    [No Abstract]   [Full Text] [Related]  

  • 4. Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1.
    Scala G; Quinto I; Ruocco MR; Mallardo M; Ambrosino C; Squitieri B; Tassone P; Venuta S
    J Virol; 1993 May; 67(5):2853-61. PubMed ID: 8386279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PU box-binding transcription factors and a POU domain protein cooperate in the Epstein-Barr virus (EBV) nuclear antigen 2-induced transactivation of the EBV latent membrane protein 1 promoter.
    Sjöblom A; Jansson A; Yang W; Laín S; Nilsson T; Rymo L
    J Gen Virol; 1995 Nov; 76 ( Pt 11)():2679-92. PubMed ID: 7595375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Epstein-Barr virus nuclear antigen 2 interacts with an EBNA2 responsive cis-element of the terminal protein 1 gene promoter.
    Zimber-Strobl U; Kremmer E; Grässer F; Marschall G; Laux G; Bornkamm GW
    EMBO J; 1993 Jan; 12(1):167-75. PubMed ID: 8381349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral and cellular factors influence the activity of the Epstein-Barr virus BCR2 and BWR1 promoters in cells of different phenotype.
    Nilsson T; Sjöblom A; Masucci MG; Rymo L
    Virology; 1993 Apr; 193(2):774-85. PubMed ID: 8384755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Epstein-Barr virus determined nuclear antigens EBNA-3A, -3B, and -3C repress EBNA-2-mediated transactivation of the viral terminal protein 1 gene promoter.
    Le Roux A; Kerdiles B; Walls D; Dedieu JF; Perricaudet M
    Virology; 1994 Dec; 205(2):596-602. PubMed ID: 7975264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Domains of the Epstein-Barr virus nuclear antigen 2 (EBNA2) involved in the transactivation of the latent membrane protein 1 and the EBNA Cp promoters.
    Sjöblom A; Nerstedt A; Jansson A; Rymo L
    J Gen Virol; 1995 Nov; 76 ( Pt 11)():2669-78. PubMed ID: 7595374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus EBNA3A and EBNA3C proteins both repress RBP-J kappa-EBNA2-activated transcription by inhibiting the binding of RBP-J kappa to DNA.
    Waltzer L; Perricaudet M; Sergeant A; Manet E
    J Virol; 1996 Sep; 70(9):5909-15. PubMed ID: 8709211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the chemokine receptor BLR2/EBI1 is specifically transactivated by Epstein-Barr virus nuclear antigen 2.
    Burgstahler R; Kempkes B; Steube K; Lipp M
    Biochem Biophys Res Commun; 1995 Oct; 215(2):737-43. PubMed ID: 7488016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr virus nuclear antigen 2 (EBNA2)-oestrogen receptor fusion proteins complement the EBNA2-deficient Epstein-Barr virus strain P3HR1 in transformation of primary B cells but suppress growth of human B cell lymphoma lines.
    Kempkes B; Zimber-Strobl U; Eissner G; Pawlita M; Falk M; Hammerschmidt W; Bornkamm GW
    J Gen Virol; 1996 Feb; 77 ( Pt 2 )():227-37. PubMed ID: 8627226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of proteins binding to the ZII element in the Epstein-Barr virus BZLF1 promoter: transactivation by ATF1.
    Wang YC; Huang JM; Montalvo EA
    Virology; 1997 Jan; 227(2):323-30. PubMed ID: 9018131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The human immunodeficiency virus type 1 Vpr transactivator: cooperation with promoter-bound activator domains and binding to TFIIB.
    Agostini I; Navarro JM; Rey F; Bouhamdan M; Spire B; Vigne R; Sire J
    J Mol Biol; 1996 Sep; 261(5):599-606. PubMed ID: 8800208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Epstein-Barr virus nuclear protein 2 domain essential for transformation is a direct transcriptional activator.
    Cohen JI; Kieff E
    J Virol; 1991 Nov; 65(11):5880-5. PubMed ID: 1656076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional cooperation of Epstein-Barr virus nuclear antigen 2 and the survival motor neuron protein in transactivation of the viral LMP1 promoter.
    Voss MD; Hille A; Barth S; Spurk A; Hennrich F; Holzer D; Mueller-Lantzsch N; Kremmer E; Grässer FA
    J Virol; 2001 Dec; 75(23):11781-90. PubMed ID: 11689659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delineation of a 16 amino acid sequence that forms a core DNA recognition motif in the Epstein-Barr virus EBNA-1 protein.
    Chen MR; Zong J; Hayward SD
    Virology; 1994 Dec; 205(2):486-95. PubMed ID: 7975250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rescue of the Epstein-Barr virus BZLF1 mutant, Z(S186A), early gene activation defect by the BRLF1 gene product.
    Adamson AL; Kenney SC
    Virology; 1998 Nov; 251(1):187-97. PubMed ID: 9813214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring the activation of stress-activated protein kinases using GAL4 fusion transactivators.
    Zheng CF; Xu L
    Methods Mol Biol; 2000; 99():145-60. PubMed ID: 10909083
    [No Abstract]   [Full Text] [Related]  

  • 20. Epstein-Barr virus transcription factors.
    Sinclair AJ; Farrell PJ
    Cell Growth Differ; 1992 Aug; 3(8):557-63. PubMed ID: 1327084
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.